Publications

DeVoss J, Hou Y, Johannes K, Lu W, Liou GI, Rinn J, Chang H, Caspi RR, Caspi R, Fong L, Anderson MS. Spontaneous autoimmunity prevented by thymic expression of a single self-antigen. The Journal of experimental medicine. 2006. PMID: 17116738


Lawrence Fong, MD

Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006. PMID: 17114665


Jo Chien, MD

Rugo H, Shtivelman E, Perez A, Vogel C, Franco S, Tan Chiu E, Melisko M, Tagliaferri M, Cohen I, Shoemaker M, Tran Z, Tripathy D. Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast cancer research and treatment. 2006. PMID: 17111207


Hope Rugo, MD

Rugo H, Shtivelman E, Perez A, Vogel C, Franco S, Tan Chiu E, Melisko M, Tagliaferri M, Cohen I, Shoemaker M, Tran Z, Tripathy D. Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast cancer research and treatment. 2006. PMID: 17111207


Michelle Melisko, MD

Kadoch C, Treseler P, Rubenstein JL. Molecular pathogenesis of primary central nervous system lymphoma. Neurosurgical focus. 2006. PMID: 17134111


James Rubenstein, MD, PhD

Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, Grigoriadis A, Sarrio D, Savage K, Dexter T, Iravani M, Fenwick K, Weber B, Hardisson D, Schmitt FC, Palacios J, Lakhani SR, Ashworth A. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006. PMID: 17121884


Alan Ashworth, PhD

Montie JE, Abrahams NA, Bahnson RR, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG, National Comprehensive Cancer Network. Bladder cancer. Clinical guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2006. PMID: 17112448


Eric Small, MD

James L. Rubenstein, Cigall Kadoch, Jon Karch, Andrew Josephson, Samar Issa, Chris Becker, Howard Schulman, Lloyd Damon, Marc A. Shuman, Sushmita Roy. Identification of CSF Biomarkers for the Diagnosis of CNS Lymphoma. Blood. 2006. PMID:


James Rubenstein, MD, PhD

Colaco SM, Chou CL, Hauer KE. Near-peer teaching in a formative clinical skills examination. Medical education. 2006. PMID: 17054629


Calvin Chou, MD

Hur J, Bell DW, Dean KL, Coser KR, Hilario PC, Okimoto RA, Tobey EM, Smith SL, Isselbacher KJ, Shioda T. Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein. Cancer research. 2006. PMID: 17047080


Ross Okimoto, MD

Yamashita Y, Krauze MT, Kawaguchi T, Noble CO, Drummond DC, Park JW, Bankiewicz KS. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro-oncology. 2006. PMID: 17018695


John Park, MD

Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU international. 2006. PMID: 16796694


Lawrence Fong, MD

Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU international. 2006. PMID: 16796694


Amy Lin, MD

Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU international. 2006. PMID: 16796694


Eric Small, MD

Sledge GW, Rugo HS, Burstein HJ. The role of angiogenesis inhibition in the treatment of breast cancer. Clinical advances in hematology & oncology : H&O. 2006. PMID: 17139244


Hope Rugo, MD

Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C, McCrae K, Menitove JE, Skikne BS, Damon L, Lopez-Plaza I, Rouault C, Crookston KP, Benjamin RJ, George J, Lin JS, Corash L, Conlan MG. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion. 2006. PMID: 17002625


Lloyd Damon, MD

Stadler WM, Halabi S, Rini B, Ernstoff MS, Davila E, Picus J, Barrier R, Small EJ, Cancer and Leukemia Group B. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer. 2006. PMID: 16909426


Eric Small, MD

Jhawer M, Rosen L, Dancey J, Hochster H, Hamburg S, Tempero M, Clendeninn N, Mani S. Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma. Investigational new drugs. 2006. PMID: 16957834


Margaret Tempero, MD

Bartlett DL, Berlin J, Lauwers GY, Messersmith WA, Petrelli NJ, Venook AP. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Annals of surgical oncology. 2006. PMID: 16955384


Alan Venook, MD

Benson AB, Bekaii-Saab T, Ben-Josef E, Blumgart L, Clary BM, Curley SA, Davila R, Earle CC, Ensminger WD, Gibbs JF, Laheru D, Langnas AN, Mulvihill SJ, Nemcek AA, Posey JA, Sigurdson ER, Sinanan M, Vauthey JN, Venook AP, Wagman LD, Yeatman TJ, National Comprehensive Cancer Network. Hepatobiliary cancers. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2006. PMID: 16948952


Alan Venook, MD